Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2, open label, randomized, active control study to find the optimal dose of P1101 by comparing antiviral activity, and safety across treatment groups in interferon naïve patients with chronic hepatitis B virus (HBV) infection.

Trial Profile

A phase 2, open label, randomized, active control study to find the optimal dose of P1101 by comparing antiviral activity, and safety across treatment groups in interferon naïve patients with chronic hepatitis B virus (HBV) infection.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 May 2018

At a glance

  • Drugs Ropeginterferon alfa-2b (Primary) ; Peginterferon alfa-2a
  • Indications Hepatitis B
  • Focus Pharmacodynamics
  • Most Recent Events

    • 17 May 2018 New trial record
    • 14 Apr 2018 Results presented at The International Liver Congress 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top